Today: August 24, 2017, 8:56 am
  
Health

Report Published: "Eosinophilic Esophagitis - Pipeline Review, H1 2017"

Recently published research from Global Markets Direct, "Eosinophilic Esophagitis - Pipeline Review, H1 2017", is now available at Fast Market Research
Report Published: "Eosinophilic Esophagitis - Pipeline Review, H1 2017"
PR-Inside.com: 2017-05-19 17:04:24
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2017, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.


Report Highlights

Full Report Details at
- www.fastmr.com/prod/1279372_eosinophilic_esophagitis.aspx?afid=7 ..

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 4 and 4 respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

* The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
* The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
* The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
* The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
* The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
* The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
* The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
* The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)

Reasons to Get this Report

* Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
* Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
* Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
* Classify potential new clients or partners in the target demographic.
* Develop tactical initiatives by understanding the focus areas of leading companies.
* Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
* Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033&afid=701

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

Press Information


Published by
Bill Thompson
18008448156
e-mail
www.fastmr.com



# 770 Words
Related Articles
More From The Author
New market study, "Global Smart Backpack Market [..]
Smart backpacks are a new generation of luggage that features some advanced technological enhancements such as embedded sensors, [..]
Now Available: Crohn's Disease (Regional Enteritis) - [..]
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease (Regional Enteritis) - [..]
Fluxion Biosciences Inc - Product Pipeline Analysis, [..]
Summary Fluxion Biosciences Inc (Fluxion) is a provider of analytical and live cell analysis tools. The company's products include [..]
Market Report, "TrendSights Analysis: Personalization", published
TrendSights Analysis: Personalization, is part of GlobalData's TrendSights series and explores how brands can provide a superior [..]
Just Published: "Overactive Bladder - Pipeline Review, [..]
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H1 [..]
 
More From Health
Invacare International take powerchairs to a new [..]
Touch screen remote Introducing next generation technology to powerchairs, Invacare is pleased to present the REM400 remote with [..]
Award Winning Ambient Noise App TaoMix 2 [..]
MONTREAL, CANADA – August 16, 2017 – Available today on Google Play, TaoMix 2 makes it easy for anyone to [..]
Riverside Clinic FB Source of Inspiring Articles [..]
Riverside Clinic is an addiction treatment service for individuals suffering due to substance abuse disorders. The Melbourne-based centre [..]
Singapore eDevelopment Biomedical Subsidiary Partners Chemia [..]
SINGAPORE, Aug 15, 2017 - (ACN Newswire) - Singapore Exchange Catalist-listed Singapore eDevelopment Limited ("SeD") announced [..]
Experience the Benefits of Croton Essential Oils [..]
New Delhi, Friday, August 11, 2017: Essential Oils are one of the most popular natural products that people all over [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.